Rivaroxaban (BAY 59-7939) - : an oral, direct Factor Xa inhibitor -has no clinically relevant interaction with naproxen
- Author
- KUBITZA, Dagmar1 ; BECKA, Michael2 ; MUECK, Wolfgang1 ; ZUEHLSDORF, Michael1
[1] Clinical Pharmacology, Pharmacometry, Bayer HealthCare AG, Wuppertal, Germany
[2] Department of Biometry, Pharmacometry, Bayer HealthCare AG, Wuppertal, Germany - Source
British journal of clinical pharmacology. 2007, Vol 63, Num 4, pp 469-476, 8 p ; ref : 20 ref
- CODEN
- BCPHBM
- ISSN
- 0306-5251
- Scientific domain
- Pharmacology drugs
- Publisher
- Blackwell Science, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- BAY 59-7939 Factor Xa inhibitor NSAID oral anticoagulant rivaroxaban
- Keyword (fr)
- Analgésique Anticoagulant Antiinflammatoire non stéroïde Antipyrétique Chimiothérapie Coagulation Factor Xa Interaction Naproxène Rivaroxaban Traitement Voie orale Arylpropionique acide dérivé Enzyme Hydrolases Inhibiteur enzyme Oxidoreductases Peptidases Prostaglandin-endoperoxide synthase Serine endopeptidases
- Keyword (en)
- Analgesic Anticoagulant Non steroidal antiinflammatory agent Antipyretic Chemotherapy Coagulation Factor Xa Interaction Naproxen Rivaroxaban Treatment Oral administration Arylpropionic acid derivatives Enzyme Hydrolases Enzyme inhibitor Oxidoreductases Peptidases Prostaglandin-endoperoxide synthase Serine endopeptidases
- Keyword (es)
- Analgésico Anticoagulante Antiinflamatorio no esteroide Antipirético Quimioterapia Coagulation Factor Xa Interacción Naproxeno Rivaroxabán Tratamiento Vía oral Arilpropionico ácido derivado Enzima Hydrolases Inhibidor enzima Oxidoreductases Peptidases Prostaglandin-endoperoxide synthase Serine endopeptidases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments
- Discipline
- General pharmacology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18588462
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1111/j.1365-2125.2006.02776.x 
https://dx.doi.org/10.1111/j.1365-2125.2006.02776.x
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2125.2006.02776.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"Rivaroxaban (BAY 59-7939) - : an oral, direct Factor Xa inhibitor -has no clinically relevant interaction with naproxen\";s:9:\"\u0000*\u0000jtitle\";s:40:\"British journal of clinical pharmacology\";s:9:\"\u0000*\u0000stitle\";s:22:\"Br. j. clin. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"63\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"469\";s:8:\"\u0000*\u0000epage\";s:3:\"476\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0306-5251\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KUBITZA\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Dagmar\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:14:\"BECKA, Michael\";i:1;s:15:\"MUECK, Wolfgang\";i:2;s:19:\"ZUEHLSDORF, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCPHBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"Rivaroxaban (BAY 59-7939) - : an oral, direct Factor Xa inhibitor -has no clinically relevant interaction with naproxen\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Blackwell Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2125.2006.02776.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"Rivaroxaban (BAY 59-7939) - : an oral, direct Factor Xa inhibitor -has no clinically relevant interaction with naproxen\";s:9:\"\u0000*\u0000jtitle\";s:40:\"British journal of clinical pharmacology\";s:9:\"\u0000*\u0000stitle\";s:22:\"Br. j. clin. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"63\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"469\";s:8:\"\u0000*\u0000epage\";s:3:\"476\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0306-5251\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KUBITZA\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Dagmar\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:14:\"BECKA, Michael\";i:1;s:15:\"MUECK, Wolfgang\";i:2;s:19:\"ZUEHLSDORF, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCPHBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"Rivaroxaban (BAY 59-7939) - : an oral, direct Factor Xa inhibitor -has no clinically relevant interaction with naproxen\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Blackwell Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2125.2006.02776.x\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2125.2006.02776.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"Rivaroxaban (BAY 59-7939) - : an oral, direct Factor Xa inhibitor -has no clinically relevant interaction with naproxen\";s:9:\"\u0000*\u0000jtitle\";s:40:\"British journal of clinical pharmacology\";s:9:\"\u0000*\u0000stitle\";s:22:\"Br. j. clin. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"63\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"469\";s:8:\"\u0000*\u0000epage\";s:3:\"476\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0306-5251\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KUBITZA\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Dagmar\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:14:\"BECKA, Michael\";i:1;s:15:\"MUECK, Wolfgang\";i:2;s:19:\"ZUEHLSDORF, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCPHBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"Rivaroxaban (BAY 59-7939) - : an oral, direct Factor Xa inhibitor -has no clinically relevant interaction with naproxen\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Blackwell Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2125.2006.02776.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"Rivaroxaban (BAY 59-7939) - : an oral, direct Factor Xa inhibitor -has no clinically relevant interaction with naproxen\";s:9:\"\u0000*\u0000jtitle\";s:40:\"British journal of clinical pharmacology\";s:9:\"\u0000*\u0000stitle\";s:22:\"Br. j. clin. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"63\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"469\";s:8:\"\u0000*\u0000epage\";s:3:\"476\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0306-5251\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KUBITZA\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Dagmar\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:14:\"BECKA, Michael\";i:1;s:15:\"MUECK, Wolfgang\";i:2;s:19:\"ZUEHLSDORF, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCPHBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"Rivaroxaban (BAY 59-7939) - : an oral, direct Factor Xa inhibitor -has no clinically relevant interaction with naproxen\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Blackwell Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1111\/j.1365-2125.2006.02776.x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:119:\"Rivaroxaban (BAY 59-7939) - : an oral, direct Factor Xa inhibitor -has no clinically relevant interaction with naproxen\";s:9:\"\u0000*\u0000jtitle\";s:40:\"British journal of clinical pharmacology\";s:9:\"\u0000*\u0000stitle\";s:22:\"Br. j. clin. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"63\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:3:\"469\";s:8:\"\u0000*\u0000epage\";s:3:\"476\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0306-5251\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"KUBITZA\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Dagmar\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:14:\"BECKA, Michael\";i:1;s:15:\"MUECK, Wolfgang\";i:2;s:19:\"ZUEHLSDORF, Michael\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"BCPHBM\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:119:\"Rivaroxaban (BAY 59-7939) - : an oral, direct Factor Xa inhibitor -has no clinically relevant interaction with naproxen\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Blackwell Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
